causal

Incentives push drug development toward late-stage

The current regulatory setup strongly incentivizes developing drugs for late-stage cancer rather than early-stage, because late-stage patients readily enroll in trials and reach endpoints faster, making trials cheaper and quicker; the prevalence of incremental drugs reflects this incentive structure, not the exhaustion of 'low-hanging fruit' or the absence of potential magic bullets.

causalpending

Speaker

Arthur Diamond

Evidence Quote

“the current set-up strongly encourages development of new drugs for later stage. And, the reason is that it's a lot cheaper to do that”

Source

Arthur Diamond on Openness to Creative Destruction— EconTalk
Created: 6/13/2026, 12:15:58 AM

Your notes

Loading notes...